• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 16, 2019

View Archived Issues

Other news to note

Phio Pharmaceuticals Corp., of Marlborough, Mass., said it entered a research collaboration with the Helmholtz Zentrum München that covers the design and development of new targets based on the company's self-delivering RNAi platform for use in cancer immunotherapies.  Read More

Financings

Deciphera Pharmaceuticals Inc., of Waltham, Mass., said it priced its registered underwritten public offering of 10.81 million shares of its common stock at $37 each. The gross proceeds are expected to be $400 million, with the underwriters being granted a 30-day option to purchase up to 1.62 million additional shares.  Read More

Clinical data for Aug. 15, 2019

Read More

Regulatory actions for Aug. 15, 2019

Read More

Aloha! Hawaii-based Cardax plans $15M follow-on public offering, move to Nasdaq

The as-much-as-$15 million follow-on public offering proposed by Honolulu-based Cardax Inc. won't move the company off the island but it's designed to move it from the OCTQB to Nasdaq. Read More

High oxygen levels may be issue in Leigh syndrome

Birth defects in mitochondrial genes can lead to devastating pediatric disorders with death within a year of birth, and when the dysfunction is milder it can lead to various types of degenerative conditions, including neurodegeneration. Read More

RNA-based therapies attracting investments, partnerships

Companies developing RNA-based therapies are now attracting significant investments, and the technologies and emerging products in the field have become desirable assets for big biopharmaceutical companies. In fact, during the past two years 20 deals have been executed, according to BioWorld data.  Read More

Generics not immune from congressional Rx pricing pressures

Congress may be on its August recess, but that doesn't mean lawmakers seeking re-election next year and presidential contenders are taking a break from their campaign against U.S. prescription drug prices. Read More

Roche's Rozlytrek wins FDA nod for ROS1 NSCLC and NTRK solid tumors

The FDA cleared Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small-cell lung cancer, also granting accelerated approval to the tyrosine kinase inhibitor for adult and pediatric patients (12 and older) with solid tumors that have a NTRK gene fusion. Read More

Harmony wins FDA approval for narcolepsy drug Wakix

Three years after its European approval, U.S. clearance for the narcolepsy drug Wakix (pitolisant) has arrived. Privately held Harmony Biosciences LLC will market the once-daily medicine, licensed from Bioprojet Societe Civile de Recherche, for the treatment of excessive daytime sleepiness (EDS) in adults with the chronic sleep disorder. Read More

TG bid far from marginal as players vie for slices of lymphoma-type's pie

Although two heavy hitters' drugs have been approved in the marginal zone lymphoma (MZL) setting where New York-based TG Therapeutics Inc. is due to report important data during the fourth quarter, the company just might have an edge with its oral PI3K-delta inhibitor, umbralisib. Read More

Big changes are coming to BioWorld! Your opinion is requested

We're working to enhance BioWorld's news services by moving to a brand-new platform later this year. Upgrades will include: same-day news delivery, improved functionality, easier accessibility on all devices, more analysis and dynamic data visualization. We value your opinion on these changes. Please take 2 minutes to complete this short survey to help guide our work: https://www.surveymonkey.com/r/Q5TK8JL Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Gilead Sciences divulges new compounds to treat herpes virus infection

    BioWorld Science
    Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe